Skip to main content

Table 6 Characteristics and outcome of canine patients treated with pump inhibitors and chemotherapy

From: Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

PATIENT AGE TUMOR PREV. TREATMENT THERAPY OUTCOME (MONTHS)
GREAT DANE 10 SPLENIC
HSA
SURGERY
METRONOMIC
METRONOMIC CR 3
WHWT 8 LSA MADISON
MOPP
MOPP CR 12
BULL MAST. 11 ALL MADISON
MOPP
MOPP CR 3
WHWT 8 LSA MADISON
MOPP
MOPP CR 8
ROTTW. 6 LSA MADISON
MOPP
MOPP CR 3
BOXER 8 LSA MADISON
MOPP
MOPP CR 7
BOXER 9 LSA MADISON
MOPP
MOPP CR 5
DOGO 10 LSA MADISON
MOPP
MOPP PR 3
WHWT 10 LSA MADISON
MOPP
MOPP PD
BOXER 10 LSA COP
MOPP
MOPP CR5+
LABRADOR 8 LSA COP
MOPP
MOPP CR5+
BULL DOG 10 SKIN LSA MADISON
MOPP
MITOXANTRONE CR5+
POODLE 12 LSA COP
MOPP
MOPP DISCONTINUED
SETTER 14 ORAL SCC MITOXANTRONE MITOXANTRONE DISCONTINUED
MIXED 11 NASAL CA MITOXANTRONE MITOXANTRONE PR 3+
MIXED 10 OSA BIOPSY CLODRONATE PR 7
MIXED 11 OSA BIOPSY CLODRONATE PR 11
SCHNAUTZER 9 OSA BIOPSY CLODRONATE DISCONTINUED
MIXED 15 TCC
BLADDER
PIROXICAM PIROXICAM SD 7+
BEAGLE 12 TCC
BLADDER
SURGERY
MITOXANTRONE
MITOXANTRONE CR 2+
ROTTWEILER 5 MELANOMA SURGERY
CARBOPLATIN
CARBOPLATIN NED 5+
MIXED 10 MAMMARY
CA
SURGERY
MITOXANTRONE
MITOXANTRONE NED 5+
MIXED 10 MAMMARY
CA
CARBOPLATIN
DOXORUBICIN
MITOXANTRONE PR 9+
MIXED 11 FSA SURGERY, ECT MITOXANTRONE NED 3+
MIXED 12 MAMMARY
CA
SURGERY
MITOXANTRONE
MITOXANTRONE NED 4+
GERMAN 8 MAMMARY SURGERY MITOXANTRONE NED 4+
SHEPHERD   CA MITOXANTRONE   
HUSKY 13 MAMMARY SURGERY MITOXANTRONE NED 5+
   CA.SA MITOXANTRONE   
  1. Abbreviations: ALL: acute lymphocytic leukemia; CA: carcinoma; CA.SA: carcinosarcoma; COP: cyclophosphamide, oncovin (vincristine), prednisone; ECT: electrochemotherapy; FSA: fibrosarcoma; HSA: hemangiosarcoma; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; OSA: osteosarcoma; SCC: squamous cell carcinoma, WHWT: west highland white terrier. +: still alive.
  2. Drugs schedule: doxorubicin 30 mg/m2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 300 mg/m2 every 21 days, mitoxantrone 6 mg/m2 every 21 days. For Madison and MOPP protocols see table 4 and 5